Pediatric Oncology Group of Ontario
Treatment of breakthrough and prevention of refractory chemotherapy-induced nausea and vomiting in pediatric cancer patients: Clinical practice guideline update
Abstract
This clinical practice guideline update provides recommendations for treating breakthrough chemotherapy-induced nausea and vomiting (CINV) and preventing refractory CINV in pediatric patients. Two systematic reviews of randomized controlled trials in adult and pediatric patients informed the recommendations. In patients with breakthrough CINV, escalation of antiemetic agents to those recommended for chemotherapy of the next higher level of emetogenic risk is strongly recommended. A similar recommendation to escalate therapy is made to prevent refractory CINV in patients who did not experience complete breakthrough CINV control and are receiving minimally or low emetogenic chemotherapy. A strong recommendation to use antiemetic agents that controlled breakthrough CINV for the prevention of refractory CINV is also made.
Source and rights
Published by Pediatric blood & cancer, 2023. The guideline itself is at the source linked here.
Prognia summarises this guideline for reference and education. It is not medical advice. Always check the official guideline and current local protocols before acting on it.
At a glance
- Organisation
- Pediatric Oncology Group of Ontario
- Published
- 2023
- Applies to
- 🇨🇦 Canada, 🇺🇸 United States, 🇬🇧 United Kingdom, 🇳🇱 Netherlands
- Scope
- International
- Journal
- Pediatric blood & cancer
More in oncology
- Non-Small Cell Lung Cancer, Version 4.2026, NCCN Clinical Practice Guidelines In OncologyNational Comprehensive Cancer Network · 2026
- Guidance for Canadian Breast Cancer Practice: National Consensus Recommendations for the Systemic Treatment of Patients with HER2+ Breast Cancer in Both the Early and Metastatic Settings (2025 Update)Research Excellence, Active Leadership Canadian Breast Cancer Alliance (REAL Alliance) [2] · 2026
